# Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction

Study · id `cardio:ct-nct07586865` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07586865](<https://clinicaltrials.gov/study/NCT07586865>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07586865

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 189 participants.

## Technical summary

Registry record NCT07586865. Randomized; quadruple masking; primary purpose treatment. Start 2026-05-18 (anticipated); primary completion 2027-08-17 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 189 participants (planned count; ClinicalTrials.gov record NCT07586865, source copy `cardio:ctgov-nct07586865-2026-05-14`, retrieved 2026-10-26)
- Planned start: 2026-05-18 (anticipated) (ClinicalTrials.gov record NCT07586865, source copy `cardio:ctgov-nct07586865-2026-05-14`, retrieved 2026-10-26)
- Primary completion: 2027-08-17 (anticipated) (ClinicalTrials.gov record NCT07586865, source copy `cardio:ctgov-nct07586865-2026-05-14`, retrieved 2026-10-26)
- Completion: 2028-05-17 (anticipated) (ClinicalTrials.gov record NCT07586865, source copy `cardio:ctgov-nct07586865-2026-05-14`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07586865, source copy `cardio:ctgov-nct07586865-2026-05-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07586865-2026-05-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction
- Condition: Acute Myocardial Infarction (AMI)
- Condition: Acute Myocardial Infarction of Anterior Wall
- Condition: Acute Myocardial Infarction With ST Elevation
- Condition: Acute Myocardial Infarction of Left Ventricle
- Condition: Acute Myocardial Infarction With ST Segment Elevation
- Intervention (Drug): Recombinant Human Thymosin Beta 4 Injection (NL005)
- Intervention (Drug): Placebo
- Lead sponsor: Beijing Northland Biotech. Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: Beijing Northland Biotech. Co., Ltd. (`cardio:org-beijing-northland-biotech-co-ltd`)

## Provenance

Content hash: b903c2c43f625fe8f4d53158e31fa542c329e9df58f3bd465ba804f8c956c9a5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
